Gilead Sciences Officer Andrew Dickinson Files Form 144 to Sell 3,000 Shares

Form 144 Analysis: Gilead Sciences, Inc. (NASDAQ: GILD)

Transaction Overview

On October 15, 2026, Andrew Dickinson, an Officer of Gilead Sciences, filed a Form 144 notice indicating the intent to sell 3,000 shares of common stock through Morgan Stanley Smith Barney LLC. The aggregate market value of the proposed transaction is $468,660.00, representing an estimated price of approximately $156.22 per share.

Security Acquisition & Trading Plan

• Acquisition Origin: The shares were originally acquired on January 31, 2024, as performance share awards directly from the issuer.
• Trading Plan: The planned sale is being executed under a pre-established Rule 10b5-1 trading plan adopted on August 29, 2024.
• Historical Activity (Past 3 Months):
  • September 15, 2026: Sold 3,000 shares for gross proceeds of $435,870.00.
  • August 17, 2026: Sold 3,000 shares for gross proceeds of $415,080.00.

Significance & Market Impact

• Impact: Low.
• Rationale: The transaction represents a routine, scheduled sale of 3,000 shares per month executed in accordance with a Rule 10b5-1 plan established over two years prior. Relative to Gilead's 1.24 billion outstanding common shares, the dilution and liquidity impact are negligible.